Tavotek Biotherapeutics focuses on the discovery and development of therapeutic medicines using targeted drug acquisition and biopharmaceutical techniques. The company provides effective treatments for various medical conditions by commercializing novel therapeutic solutions.
Funding
$55M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including cancers, autoimmune conditions, and infectious diseases, lack effective treatments due to the difficulty in targeting specific proteins, especially those within cells or those that are difficult to access due to the blood-brain barrier. Traditional methods of drug discovery and development often fail to address these challenges, leaving significant unmet medical needs.
Solution
Tavotek Biotherapeutics is a biopharmaceutical company focused on discovering and developing therapeutic medicines to address unmet medical needs in cancers, autoimmune conditions, and infectious diseases. The company utilizes three R&D platforms: TavoSelect™ (a phage display library for targeting membrane proteins, intracellular proteins, and antigens behind the blood-brain barrier), TavoPrecise™ (a platform for developing tissue-specific biologics), and TavoELITE™ (a platform for targeting intracellular targets). These platforms enable the company to discover and develop novel biologics for a diverse pipeline of product candidates.
Target Audience
The primary target audience includes patients suffering from debilitating diseases with significant unmet medical needs, as well as pharmaceutical companies seeking collaboration or licensing opportunities for novel therapeutic assets.
Features
- TavoSelect™ phage display library for identifying antibodies and biomolecules against difficult-to-reach targets.
- TavoPrecise™ platform for engineering tissue-specific biologics, enhancing targeted drug delivery.
- TavoELITE™ platform for developing therapies against traditionally "undruggable" intracellular targets.
- A pipeline of product candidates focused on cancers, autoimmune conditions, and infectious diseases.
- Multispecific biologics development capabilities.